Accessibility Menu
Vanda Pharmaceuticals logo

Vanda Pharmaceuticals(NASDAQ) VNDA

Market Cap$310.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-47%
5 Year-71%
1 Year+10%
1 Month-14%
$5.06
-1.94%
-0.10Today
Vanda Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 5.162026-07-28
Vanda Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.84%USD 5.482026-07-21
1 month-14.14%USD 6.012026-06-26
3 month-26.81%USD 7.052026-04-29
Year to date-41.5%USD 8.822025-12-31
1 year+9.79%USD 4.702025-07-28
3 year-13.13%USD 5.942023-07-28
5 year-71.12%USD 17.872021-07-29
Since inception-46.69%USD 9.682006-04-12

Vanda Pharmaceuticals Financials at a Glance

Market Cap

$310.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$217.78M

Net Income (TTM)

-$239.55M

EPS (TTM)

-$4.05

P/E Ratio

-1.27

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$5.06

Volume

781,644.06

Open

$5.13

Previous Close

$5.05

Daily Range

$4.94 - $5.19

52-Week Range

$4.14 - $9.94

Estimated Earnings Date

Jul 30, 2026

VNDA News

Doctor and patient talking.

Should You Invest in This Under-the-Radar Weight Loss Stock?

Prosper Junior BakinyNov 30, 2025
Foolcom-Featured.png

Vanda (VNDA) Q2 Revenue Rises 4%

Motley Fool Markets TeamAug 1, 2025
Medical professional with hand on head

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today

Eric VolkmanSep 19, 2024
Thumb down

Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

Keith SpeightsApr 17, 2024
vir biotechnology

Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday

James HalleySep 5, 2023
Medical professional holding dollar sign paperweight

Why Vanda Pharmaceuticals Stock Crawled Higher Today

Eric VolkmanFeb 9, 2023
Doctor boy leg

Here's Why Vanda Pharmaceuticals Jumped Higher Today

Brian Orelli, PhDDec 2, 2020
GettyImages-1138947312

1 Pharma Stock to Avoid at All Costs

Zhiyuan SunMay 15, 2020
Page 1

VNDA: Motley Fool Moneyball Superscore

51

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vanda Pharmaceuticals

Vanda makes medicines for people with rare sleep problems. It also helps patients with schizophrenia and multiple sclerosis. These drugs aim to improve daily life for these individuals.

What Is on the Pharmacy Shelf?

  • Psychiatric Treatments: Fanapt oral tablets treat schizophrenia and manic episodes associated with bipolar I disorder.
  • Sleep Disorder Medicines: HETLIOZ capsules treat Non-24-Hour Sleep-Wake Disorder, a condition where internal clocks do not match the day-night cycle.
  • Multiple Sclerosis Care: PONVORY tablets treat adults with relapsing forms of multiple sclerosis, a disease where the immune system attacks nerves.
  • Motion Sickness Prevention: NEREUS capsules help prevent vomiting caused by movement during travel, approved by regulators in December 2025.

New Drugs and Big Deals

  • Purchased the U.S. and Canadian rights for PONVORY from Actelion Pharmaceuticals Ltd. in December 2023.
  • Entered an exclusive global license agreement with AnaptysBio, Inc. in January 2025 to develop a new psoriasis treatment.
  • Started a research and development collaboration with OliPass Corporation in 2022 to develop gene-modifying molecules.
  • Launched Fanapt for the treatment of manic or mixed episodes in bipolar I disorder in late 2024.

Using Genetics to Improve Care

Vanda uses pharmacogenetics, the study of how genes affect drug response, to create more effective and personalized treatments. The company follows a virtual business model, hiring third-party partners like Patheon to manufacture its products instead of owning factories.

A Look at the Books

  • Revenue reached $57.2 million in Q4 2025, up 7.6% from $53.2 million in Q4 2024.
  • Net income fell to a loss of $141.2 million in Q4 2025, which deepened from a $4.9 million loss year-over-year.
  • Free cash flow was negative $29.5 million in Q4 2025, compared to negative $2 million in Q4 2024.
  • Full-year net sales for Fanapt totaled $117.3 million in 2025, while HETLIOZ sales reached $71.4 million.

The Bottom Line

Vanda has expanded from a niche specialist in sleep disorders into a diversified company treating psychiatric and autoimmune conditions. Its long-term path depends on successfully launching new products while defending its existing drug patents against generic manufacturers.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

533

CEO

Mihael Hristos Polymeropoulos, MD

Website

www.vandapharma.com

Headquarters

Washington, DC 20037, US

VNDA Financials

Key Financial Metrics (TTM)

Gross Margin

92.46%

Operating Margin

-73.64%

Net Income Margin

-109.99%

Return on Equity

-61.41%

Return on Capital

-44.49%

Return on Assets

-55.26%

Earnings Yield

-78.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$310.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.14M

Volume

781.64K

Avg. Volume

982.74K

Financials (TTM)

Gross Profit

$201.36M

Operating Income

-$160.36M

EBITDA

-$136.24M

Operating Cash Flow

-$126.51M

Capital Expenditure

-$783.00K

Free Cash Flow

-$127.30M

Cash & ST Invst.

$202.31M

Total Debt

$13.07M

Vanda Pharmaceuticals Performance Analysis

Vanda Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 254,382,000-5.3%
20232023-12-31USD 192,640,000-24.3%
20242024-12-31USD 198,772,0003.2%
20252025-12-31USD 216,105,0008.7%
Vanda Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.1%
Q32025-09-307.0%
Q42025-12-311.7%
Q12026-03-31-9.6%
Vanda Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.11-81.1%
20232023-12-31USD 0.04-60.4%
20242024-12-31USD -0.33N/A
20252025-12-31USD -3.741051.2%
Vanda Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.0%
Q32025-09-3017.4%
Q42025-12-31-528.9%
Q12026-03-3165.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$51.72M

+3.4%

Gross Profit

$46.57M

+0.1%

Gross Margin

90.05%

N/A

Market Cap

$310.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$582.18K

N/A

Employees

533

N/A

Net Income

-$48.57M

-64.7%

EBITDA

-$44.90M

-44.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$202.31M

-40.7%

Total Debt

$13.07M

+11.3%

Accounts Receivable

$56.88M

+27.5%

Inventory

$1.70M

-11.6%

Long Term Debt

$7.05M

-4.1%

Short Term Debt

$6.02M

+37.1%

Return on Assets

-55.26%

N/A

Return on Invested Capital

-53.82%

N/A

Free Cash Flow

-$50.44M

-50.2%

Operating Cash Flow

-$50.22M

-51.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRDAEntrada Therapeutics, Inc.
$6.55+12.35%
AVIRAtea Pharmaceuticals, Inc.
$4.62+2.44%
CAPRCapricor Therapeutics, Inc.
$6.57+0.00%
SGMTSagimet Biosciences Inc.
$7.04-3.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.41-0.06%
TAT&T
$23.94-0.03%
SMRNuScale Power
$7.59-0.08%
ORCLOracle
$117.74-0.02%

Questions About VNDA

What is the current price of Vanda Pharmaceuticals?

Vanda Pharmaceuticals is trading at $5.05 per share.

What is the 52-week range for Vanda Pharmaceuticals?

Over the past 52 weeks, Vanda Pharmaceuticals has traded between $4.14 and $9.94.

How much debt does Vanda Pharmaceuticals have?

As of the most recent reporting period, Vanda Pharmaceuticals reported total debt of $13.07M.

How much cash does Vanda Pharmaceuticals have on hand?

Vanda Pharmaceuticals reported $54.03M in cash and cash equivalents in its most recent financial results.

What is Vanda Pharmaceuticals’s dividend yield?

Vanda Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services